On September 19, 2016 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, reported that it will present preclinical data, and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ (atezolizumab), in both oral and poster presentations at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper): Translating Science into Survival, which is taking place from September 25-28 in New York (Press release, Corvus Pharmaceuticals, SEP 19, 2016, View Source;p=RssLanding&cat=news&id=2204373 [SID:SID1234515202]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Following are details of the oral and poster presentations.
ABSTRACT TITLE: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies
PRESENTER: Stephen Willingham, Ph.D., senior scientist, Corvus
ORAL SESSION: Plenary Session 2: New Checkpoints
ORAL SESSION DATE, TIME AND LOCATION: Sunday, September 25, 1:30-4:40 p.m. ET, Sheraton Metropolitan Ballroom, Sheraton New York Times Square Hotel
POSTER SESSION: Poster Session A: New Checkpoints
POSTER NUMBER: A048
POSTER PRESENTATION DATE, TIME AND LOCATION: Sunday, September 25, 5:00-7:30 p.m. ET, Americas Hall I, New York Hilton Midtown